Compare Vaxcyte Inc. Common Stock (PCVX) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vaxcyte Inc. Common Stock vs Tilray Brands Inc — how do they compare? Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B), while Tilray Brands Inc trades at $3.11 (market cap $481.79M). The key difference: Vaxcyte Inc. Common Stock is far larger — about 21.8× Tilray Brands Inc's market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vaxcyte Inc. Common Stock for 0 Days and Tilray Brands Inc for 31 Days on average.
| PCVX | TLRY | |
|---|---|---|
Market Cap | $10.51B | $481.79M |
Volume | 2,644,694 | 4,056,443 |
Sector | Health | Health |
52-Week High | $73.82 | $16.80 |
52-Week Low | $40.32 | $3.14 |
Typical Hold Time | 0 Days | 31 Days |
Enterprise Value | $9.14B | $635.71M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Tilray Brands (TLRY) trades at $3.27, down 2.68% on the day and near 52-week lows, with bearish technical signals dominating. The company reported $821 million in revenue for 2025 but posted a massive $2.19 billion net loss due to impairment charges. Recent earnings misses and negative cash flow from operations highlight ongoing profitability challenges despite analyst consensus pointing to significant upside potential.
TLRY presents a high-risk opportunity with substantial analyst price target divergence. While valuation metrics appear attractive (P/S 0.4x, P/B 0.3x), persistent losses and cash burn require careful monitoring. The stock's fate hinges on cannabis reform progress and the company's ability to achieve sustainable profitability amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vaxcyte Inc. Common Stock
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
